FDA-Regulated Research(Answered)2022

A sponsor proposes research to evaluate reengineering a commercially available pacemaker. It is hoped that the new pacemaker will pose fewer risks to individuals when compared to the current commercially available product. How should this device be classified? Significant risk device An adult with attention deficit hyperactivity disorder (ADHD) presents to a physician. To date, no behavioral or drug interventions have proven useful. The physician has just read several reports about a drug that is approved and marketed for another indication, but has shown some benefit for ADHD. The physician wants to prescribe this drug, in the labeled marketed dose, for the individual patient. Which of the following would be the most appropriate course of action? Treat the patient with the drug based on physician's best medical judgment An investigator proposes to study a marketed product sold to treat high blood pressure in individuals over age 12 using a liquid formulation for children under age 12. The drug sponsor hopes that the information from the research can be used to change the labeling for use of the drug in younger children. Which of the following is the investigator's most appropriate course of action? Submit the research protocol to the IRB for review and submit an IND application to the FDA before conducting the research The FDA's regulations related to electronic records and electronic signatures (21 CFR Part 11) is intended to: Allow the use of electronic documents and signatures in the regulatory process for drugs and devices. An academic medical center is selecting a new database system for clinical research. The system needs to be "Part 11 compliant" in order to allow: The medical center to replace the use of paper records with electronic records for its research.